The present invention belongs to the field of the pharmaceutical industry and relates to a pharmaceutical composition comprising an intragranular phase and an extragranular phase, and relates to 2-({6-[(3R) -3-aminopiperidin-1-yl] of the pharmaceutically active ingredient (API). ] -3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -yl} methyl) benzonitrile or a pharmaceutically acceptable salt thereof is present in the intragranular phase, The internal phase does not contain crystalline cellulose. The invention further relates to its manufacture.本発明は製薬業界の分野に属し、粒内相及び粒外相を含む医薬組成物に関し、前記医薬活性成分（ＡＰＩ)の２－（｛６－［（３Ｒ)－３－アミノピペリジン－１－イル］－３－メチル－２，４－ジオキソ－３，４－ジヒドロピリミジン－１（２Ｈ)－イル｝メチル)ベンゾニトリルまたはその医薬的に許容され得る塩は粒内相中に存在し、前記粒内相は結晶セルロースを含んでいない。更に、本発明はその製造に関する。
